tetano
Editor, Senior Moderator
Am J Gastroenterol
. 2020 Jun 3.
doi: 10.14309/ajg.0000000000000732. Online ahead of print.
Lipase Elevation in Patients With COVID-19
Julia McNabb-Baltar[SUP] 1 2 [/SUP], David X Jin[SUP] 1 2 [/SUP], Amit S Grover[SUP] 2 3 [/SUP], Walker D Redd[SUP] 2 4 [/SUP], Joyce C Zhou[SUP] 2 [/SUP], Kelly E Hathorn[SUP] 2 5 [/SUP], Thomas R McCarty[SUP] 2 5 [/SUP], Ahmad N Bazarbashi[SUP] 2 5 [/SUP], Lin Shen[SUP] 2 5 [/SUP], Walter W Chan[SUP] 2 5 [/SUP]
Affiliations
Abstract
Introduction: Although coronavirus disease (COVID-19) has been associated with gastrointestinal manifestations, its effect on the pancreas remains unclear. We aimed to assess the frequency and characteristics of hyperlipasemia in patients with COVID-19.
Methods: A retrospective cohort study of hospitalized patients across 6 US centers with COVID-19.
Results: Of 71 patients, 9 (12.1%) developed hyperlipasemia, with 2 (2.8%) greater than 3 times upper limit of normal. No patient developed acute pancreatitis. Hyperlipasemia was not associated with poor outcomes or symptoms.
Discussion: Although a mild elevation in serum lipase was observed in some patients with COVID-19, clinical acute pancreatitis was not seen.
. 2020 Jun 3.
doi: 10.14309/ajg.0000000000000732. Online ahead of print.
Lipase Elevation in Patients With COVID-19
Julia McNabb-Baltar[SUP] 1 2 [/SUP], David X Jin[SUP] 1 2 [/SUP], Amit S Grover[SUP] 2 3 [/SUP], Walker D Redd[SUP] 2 4 [/SUP], Joyce C Zhou[SUP] 2 [/SUP], Kelly E Hathorn[SUP] 2 5 [/SUP], Thomas R McCarty[SUP] 2 5 [/SUP], Ahmad N Bazarbashi[SUP] 2 5 [/SUP], Lin Shen[SUP] 2 5 [/SUP], Walter W Chan[SUP] 2 5 [/SUP]
Affiliations
- PMID: 32496339
- DOI: 10.14309/ajg.0000000000000732
Abstract
Introduction: Although coronavirus disease (COVID-19) has been associated with gastrointestinal manifestations, its effect on the pancreas remains unclear. We aimed to assess the frequency and characteristics of hyperlipasemia in patients with COVID-19.
Methods: A retrospective cohort study of hospitalized patients across 6 US centers with COVID-19.
Results: Of 71 patients, 9 (12.1%) developed hyperlipasemia, with 2 (2.8%) greater than 3 times upper limit of normal. No patient developed acute pancreatitis. Hyperlipasemia was not associated with poor outcomes or symptoms.
Discussion: Although a mild elevation in serum lipase was observed in some patients with COVID-19, clinical acute pancreatitis was not seen.